Liraglutide Reduces BMI When Lifestyle Change Isn't Enough

When lifestyle changes aren't enough, a team of international researchers including Pitt Pediatrics' Silva Arslanian, MD, Richard L. Day Professor of Pediatrics and scientific director of the Center for Pediatric Research in Obesity and Metabolism, found a significant BMI reduction in children with obesity after taking liraglutide.

In a recent phase 3 clinical trial conducted over a 56-week treatment period and 26-week follow-up period, patients were randomly assigned placebo or liraglutide injections. A significant BMI reduction of at lesat five percent was observed in nearly 70 percent of patients receiving liraglutide. 

This trial was sponsored by Novo Nordisk and conducted at a total of 32 sites in Belgium, Mexico, Russia, Sweden, and the United States.

Read the full article here.

Interested in receiving specialty-specific information? Register for UPMC Physician Resources to get emerging research, clinical updates, and free CME straight to your inbox.